Method of treating atopic dermatitis with antibody to zcytor17 ligand

• US 8,778,344 B2
• Filed: 01/26/2012
• Issued: 07/15/2014
• Est. Priority Date: 01/18/2002
• Status: Expired due to Fees

• Current Assignee: Zymogenetics Incorporated (Bristol-Myers Squibb Company)
• Original Assignee: Zymogenetics Incorporated (Bristol-Myers Squibb Company)
• Inventors: Sprecher, Cindy A., Kuijper, Joseph L., Dasovich, Maria M., Grant, Francis J., Gross, Jane A., Hammond, Angela K.
• Primary Examiner(s): MERTZ, PREMA MARIA
• Application Number:
  US13/359,049
• Publication Number:
  US 20130156695A1
• Time in Patent Office: 901 Days
• Field of Search: 424/1.53, 424/133.1, 424/135.1, 424/139.1, 424/178.1, 424/183.1, 424/9.3, 424/9.6, 424/145.1
• US Class Current: 424/145.1
• CPC Class Codes: A01K 2217/05 Animals comprising random inserted nucleic acids (transgenic)
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: A61P 1/02 Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
• CPC Class Codes: A61P 1/04 for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
• CPC Class Codes: A61P 11/00 Drugs for disorders of the respiratory system
• CPC Class Codes: A61P 11/06 Antiasthmatics
• CPC Class Codes: A61P 15/08 for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
• CPC Class Codes: A61P 17/06 Antipsoriatics
• CPC Class Codes: A61P 19/02 for joint disorders, e.g. arthritis, arthrosis
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 31/04 Antibacterial agents
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 37/00 Drugs for immunological or allergic disorders
• CPC Class Codes: A61P 37/02 Immunomodulators
• CPC Class Codes: A61P 37/08 Antiallergic agents antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: A61P 7/00 Drugs for disorders of the blood or the extracellular fluid
• CPC Class Codes: C07K 14/47 from mammals
• CPC Class Codes: C07K 14/52 Cytokines; Lymphokines; Interferons
• CPC Class Codes: C07K 16/24 against cytokines, lymphokines or interferons
• CPC Class Codes: C07K 2317/24 : containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Abstract

The present invention relates to zcytor17lig polynucleotide, polypeptide and anti-zcytor17 antibody molecules. The zcytor17lig is a novel cytokine. The polypeptides may be used within methods for stimulating the immune system, and proliferation and/or development of hematopoietic cells in vitro and in vivo. The present invention also includes methods for producing the protein, uses therefor and antibodies thereto.

Claims

1. A method of treating an inflammatory disease in a mammal comprising administering to the mammal a therapeutically effective amount of an isolated monoclonal antibody or antigen-binding fragment thereof that specifically binds a polypeptide consisting of amino acid residues 27-164 of SEQ ID NO:

2, wherein the inflammatory disease is atopic dermatitis.

2. The method of claim 1, wherein the monoclonal antibody or antigen-binding fragment thereof is humanized.

3. The method of claim 1, wherein the monoclonal antibody or antigen-binding fragment thereof is human.

4. The method of claim 1, wherein the monoclonal antibody or antigen-binding fragment thereof reduces the binding of the polypeptide to its receptor.

5. The method of claim 4, wherein the monoclonal antibody or antigen-binding fragment thereof reduces the signal transduction in the cell expressing the receptor.

6. The method of claim 1, wherein the antigen-binding fragment is a F(ab′

)₂, Fab or a single chain Fv.

7. The method of claim 1, wherein the monoclonal antibody or antigen-binding fragment thereof further comprises a radionuclide, enzyme, substrate, cofactor, fluorescent marker, chemiluminescent marker, peptide tag, magnetic particle, drug, or toxin.

8. A method of treating an inflammatory disease in a mammal comprising administering to the mammal a therapeutically effective amount of a composition comprising an isolated monoclonal antibody or antigen-binding fragment thereof that specifically binds a polypeptide consisting of amino acid residues 27-164 of SEQ ID NO:

2, and a pharmaceutically acceptable carrier, wherein the inflammatory disease is atopic dermatitis.

9. The method of claim 8, wherein the monoclonal antibody or antigen-binding fragment thereof is humanized.

10. The method of claim 8, wherein the monoclonal antibody or antigen-binding fragment thereof is human.

11. The method of claim 8, wherein the monoclonal antibody or antigen-binding fragment thereof reduces the binding of the polypeptide to its receptor.

12. The method of claim 11, wherein the monoclonal antibody or antigen-binding fragment thereof reduces the signal transduction in the cell expressing the receptor.

13. The method of claim 8, wherein the antigen-binding fragment is a F(ab′

)₂, Fab or a single chain Fv.

14. The method of claim 8, wherein the monoclonal antibody or antigen-binding fragment thereof further comprises a radionuclide, enzyme, substrate, cofactor, fluorescent marker, chemiluminescent marker, peptide tag, magnetic particle, drug, or toxin.